Key Takeaways
- • Lumira Ventures announced the first closing of Fund V with a target final size of US$200 million (C$275 million), representing the firm's seventh investment fund and strengthening its position as Canada's largest life sciences venture capital firm.
- • Fund V has already deployed capital with a US$52 million Series B financing for a pre-commercial-stage medical device company, demonstrating active deal flow and investment readiness.
- • Co-founder Gerry Brunk was named Managing Partner, signaling the firm's succession planning and commitment to next-generation investment talent leadership during this growth phase.
- • Since 2024, Lumira-backed portfolio companies have exited 7 companies at cumulative transaction value exceeding US$8 billion, raised US$1.6 billion in follow-on capital, secured 7 new FDA product approvals, and forged relationships with over 20 strategic partners.
- • Over its multi-decade operating history, Lumira portfolio companies have generated more than US$100 billion in cumulative revenue, achieved over 40 regulatory approvals, delivered 25+ exits through IPOs and strategic acquisitions, and touched the lives of more than 15 million patients globally.
Summary
Lumira Ventures announced the first closing of Lumira Ventures V, LP, its latest healthcare venture capital fund targeting transformative biotechnology and medical technology companies across North America. With a target final size of US$200 million (C$275 million), Fund V represents the firm's seventh investment fund to date and underscores Lumira's strategic expansion into secondary North American venture ecosystems while maintaining its Canadian leadership position. The fund has already completed its initial deployment with a US$52 million Series B financing for a pre-commercial-stage medical device company, indicating strong deal sourcing capabilities and immediate capital deployment capacity.
The announcement coincides with significant leadership transitions at Lumira. Co-founder Gerry Brunk has been promoted to Managing Partner, placing him at the center of Fund V's strategy and execution as well as the firm's next phase of growth. This succession planning move reflects Lumira's commitment to developing and promoting next-generation investment talent within the organization.
Lumira's track record demonstrates substantial exit value creation and portfolio company performance. Since 2024 alone, the firm has successfully exited 7 portfolio companies with cumulative transaction value exceeding US$8 billion, while its companies have collectively raised more than US$1.6 billion in follow-on capital, established relationships with over 20 strategic partners, and obtained 7 new FDA product approvals. Over its multi-decade history, Lumira-backed companies have generated cumulative revenue exceeding US$100 billion, achieved over 40 regulatory approvals, completed 25+ exits through IPOs and strategic acquisitions, and delivered innovations that have impacted more than 15 million patients globally. This performance record positions Fund V within a proven institutional framework for healthcare venture investing across North America.
The announcement coincides with significant leadership transitions at Lumira. Co-founder Gerry Brunk has been promoted to Managing Partner, placing him at the center of Fund V's strategy and execution as well as the firm's next phase of growth. This succession planning move reflects Lumira's commitment to developing and promoting next-generation investment talent within the organization.
Lumira's track record demonstrates substantial exit value creation and portfolio company performance. Since 2024 alone, the firm has successfully exited 7 portfolio companies with cumulative transaction value exceeding US$8 billion, while its companies have collectively raised more than US$1.6 billion in follow-on capital, established relationships with over 20 strategic partners, and obtained 7 new FDA product approvals. Over its multi-decade history, Lumira-backed companies have generated cumulative revenue exceeding US$100 billion, achieved over 40 regulatory approvals, completed 25+ exits through IPOs and strategic acquisitions, and delivered innovations that have impacted more than 15 million patients globally. This performance record positions Fund V within a proven institutional framework for healthcare venture investing across North America.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.